FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2751684866> ?p ?o ?g. }

• W2751684866 endingPage "84275" @default.
• W2751684866 startingPage "84258" @default.
• W2751684866 abstract "// Viviana Bustos 1 , Áine M. Nolan 1 , Anke Nijhuis 2 , Harry Harvey 1 , Alexandra Parker 2 , Richard Poulsom 2 , Jean McBryan 1 , Warren Thomas 1 , Andrew Silver 2 and Brian J. Harvey 1 1 Department of Molecular Medicine, Education and Research Centre, Beaumont Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland 2 Centre for Digestive Diseases, National Centre for Bowel Research and Surgical Innovation, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK Correspondence to: Brian J. Harvey, email: brianharvey@rcsi.ie Keywords: estrogen, GPER, VEGF, hypoxia, colorectal cancer Received: March 29, 2017      Accepted: July 26, 2017      Published: September 06, 2017 ABSTRACT The estrogen receptor ERβ is the predominant ER subtype expressed in normal well-differentiated colonic epithelium. However, ERβ expression is lost under the hypoxic microenvironment as colorectal cancer (CRC) malignancy progresses. This raises questions about the role of signalling through other estrogen receptors such as ERα or G-protein coupled estrogen receptor (GPER, GPR30) by the estrogen 17β-estradiol (E2) under hypoxic conditions after ERβ is lost in CRC progression. We tested the hypothesis that E2 or hypoxia can act via GPER to contribute to the altered phenotype of CRC cells. GPER expression was found to be up-regulated by hypoxia and E2 in a panel of CRC cell lines. The E2-modulated gene, Ataxia telangiectasia mutated ( ATM ), was repressed in hypoxia via GPER signalling. E2 treatment enhanced hypoxia-induced expression of HIF1-α and VEGFA, but repressed HIF1-α and VEGFA expression under normoxic conditions. The expression and repression of VEGFA by E2 were mediated by a GPER-dependent mechanism. E2 treatment potentiated hypoxia-induced CRC cell migration and proliferation, whereas in normoxia, cell migration and proliferation were suppressed by E2 treatment. The effects of E2 on these cellular responses in normoxia and hypoxia were mediated by GPER. In a cohort of 566 CRC patient tumor samples, GPER expression significantly associated with poor survival in CRC Stages 3-4 females but not in the stage-matched male population. Our findings support a potentially pro-tumorigenic role for E2 in ERβ-negative CRC under hypoxic conditions transduced via GPER and suggest a novel route of therapeutic intervention through GPER antagonism." @default.
• W2751684866 created "2017-09-15" @default.
• W2751684866 creator A5009649922 @default.
• W2751684866 creator A5039122391 @default.
• W2751684866 creator A5043932592 @default.
• W2751684866 creator A5052431651 @default.
• W2751684866 creator A5067099967 @default.
• W2751684866 creator A5070737419 @default.
• W2751684866 creator A5073409354 @default.
• W2751684866 creator A5075802397 @default.
• W2751684866 creator A5083571747 @default.
• W2751684866 creator A5091535593 @default.
• W2751684866 date "2017-09-06" @default.
• W2751684866 modified "2023-09-25" @default.
• W2751684866 title "GPER mediates differential effects of estrogen on colon cancer cell proliferation and migration under normoxic and hypoxic conditions" @default.
• W2751684866 cites W1493048246 @default.
• W2751684866 cites W1556385426 @default.
• W2751684866 cites W1581791288 @default.
• W2751684866 cites W1964649844 @default.
• W2751684866 cites W1966272418 @default.
• W2751684866 cites W1974148528 @default.
• W2751684866 cites W1981989535 @default.
• W2751684866 cites W1986332208 @default.
• W2751684866 cites W1987875441 @default.
• W2751684866 cites W1989070173 @default.
• W2751684866 cites W1991772212 @default.
• W2751684866 cites W1995318696 @default.
• W2751684866 cites W2007406157 @default.
• W2751684866 cites W2009330908 @default.
• W2751684866 cites W2063694007 @default.
• W2751684866 cites W2065892129 @default.
• W2751684866 cites W2096913799 @default.
• W2751684866 cites W2097128357 @default.
• W2751684866 cites W2098134455 @default.
• W2751684866 cites W2098972920 @default.
• W2751684866 cites W2099540110 @default.
• W2751684866 cites W2101013822 @default.
• W2751684866 cites W2104924004 @default.
• W2751684866 cites W2107220744 @default.
• W2751684866 cites W2107277218 @default.
• W2751684866 cites W2128488659 @default.
• W2751684866 cites W2131525177 @default.
• W2751684866 cites W2133211243 @default.
• W2751684866 cites W2133946921 @default.
• W2751684866 cites W2141130185 @default.
• W2751684866 cites W2141179087 @default.
• W2751684866 cites W2151806794 @default.
• W2751684866 cites W2153895029 @default.
• W2751684866 cites W2154941270 @default.
• W2751684866 cites W2157524128 @default.
• W2751684866 cites W2163268336 @default.
• W2751684866 cites W2165502223 @default.
• W2751684866 cites W2176047031 @default.
• W2751684866 cites W2192080449 @default.
• W2751684866 cites W2290627980 @default.
• W2751684866 cites W2604652125 @default.
• W2751684866 cites W4288283969 @default.
• W2751684866 doi "https://doi.org/10.18632/oncotarget.20653" @default.
• W2751684866 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5663593" @default.
• W2751684866 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29137421" @default.
• W2751684866 hasPublicationYear "2017" @default.
• W2751684866 type Work @default.
• W2751684866 sameAs 2751684866 @default.
• W2751684866 citedByCount "39" @default.
• W2751684866 countsByYear W27516848662018 @default.
• W2751684866 countsByYear W27516848662019 @default.
• W2751684866 countsByYear W27516848662020 @default.
• W2751684866 countsByYear W27516848662021 @default.
• W2751684866 countsByYear W27516848662022 @default.
• W2751684866 countsByYear W27516848662023 @default.
• W2751684866 crossrefType "journal-article" @default.
• W2751684866 hasAuthorship W2751684866A5009649922 @default.
• W2751684866 hasAuthorship W2751684866A5039122391 @default.
• W2751684866 hasAuthorship W2751684866A5043932592 @default.
• W2751684866 hasAuthorship W2751684866A5052431651 @default.
• W2751684866 hasAuthorship W2751684866A5067099967 @default.
• W2751684866 hasAuthorship W2751684866A5070737419 @default.
• W2751684866 hasAuthorship W2751684866A5073409354 @default.
• W2751684866 hasAuthorship W2751684866A5075802397 @default.
• W2751684866 hasAuthorship W2751684866A5083571747 @default.
• W2751684866 hasAuthorship W2751684866A5091535593 @default.
• W2751684866 hasBestOaLocation W27516848661 @default.
• W2751684866 hasConcept C121608353 @default.
• W2751684866 hasConcept C126322002 @default.
• W2751684866 hasConcept C134018914 @default.
• W2751684866 hasConcept C166471694 @default.
• W2751684866 hasConcept C2777164284 @default.
• W2751684866 hasConcept C502942594 @default.
• W2751684866 hasConcept C526805850 @default.
• W2751684866 hasConcept C530470458 @default.
• W2751684866 hasConcept C71924100 @default.
• W2751684866 hasConcept C84606932 @default.
• W2751684866 hasConceptScore W2751684866C121608353 @default.
• W2751684866 hasConceptScore W2751684866C126322002 @default.
• W2751684866 hasConceptScore W2751684866C134018914 @default.
• W2751684866 hasConceptScore W2751684866C166471694 @default.
• W2751684866 hasConceptScore W2751684866C2777164284 @default.
• W2751684866 hasConceptScore W2751684866C502942594 @default.

• next